Available Technologies

No technologies match these criteria.
Schedule UC TechAlerts to receive an email when technologies are published that match this search. Click on the Save Search link above

Find technologies available for licensing from UCSF.


Novel human monoclonal antibodies recognize a cell surface antigen that has limited normal tissue expression but is highly overexpressed in several types of cancers, including mesothelioma, melanoma, head and neck cancer, lung cancer, glioblastoma multiforme, pancreatic cancer, ovarian cancer, breast cancer, prostate cancer, cervical cancer, skin cancer and testicular cancer. The antibodies can block tumor invasion, self-renewal and have potential to modulate immune effector cell function.

“PROTAC-SPARK”: A Genetically-encoded Fluorescent Reporter Platform for Studying PROTAC Interaction Kinetics in Living Cells

This novel class of genetically-encoded fluorescent reporters can be used as powerful tools to study kinetics of protein targeting chimeras (PROTACs) in living cells. These bright, reversible reporters have a large dynamic range and fast kinetics, demonstrating significant advantages over traditional FRET-based fluorescent reporters. This highly-customizable reporter system is ideal for designing novel cell assays to quickly test protein-protein interactions with quantitative results.

“CT Mucus Score” - A New Scoring System that Quantifies Airway Mucus Impaction Using CT Scans

A novel method to measure airway mucus plugging using CT images from patients with asthma or chronic obstructive pulmonary disease (COPD) patients.


UCSF researchers have developed a novel gut microbiome-based diagnostic test for early-life identification of atopy or asthma risk in children.

Neural Implant Platform for Direct and Large Surface-area Access to Brain

This invention is a neural implantation platform permitting large scale recording of brain activity, suitable for both animals and humans. The use of advanced silicone materials in the design allows for greater access to brain surface area than currently existing implantation platforms.

Potent TMEM16A Small Molecule Treatment for Inflammatory and Reactive Airway Diseases, Asthma, Hypertension, Pain and Cancer

A novel class of 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides (AACTs) as potent TMEM16A inhibitors

The Use Of Parathyroid Gland Cells And Their Secreted Factors To Promote Islet Beta Cell Engraftments

This invention identifies a novel method to increases survival of transplanted islets in extra-hepatic sites (subcutaneous and intramuscular) through co-transplantation of pancreatic islet beta cells together with parathyroid glands (PTGs). This treatment can successfully be used for patients with type I diabetes.

Novel Compounds that Target Her3

UCSF researchers have developed a new class of small molecule ligands that specifically target HER3, a receptor tyrosine kinase implicated in numerous cancers.